Kintor Pharmaceutical Limited
22 MAY 2020
Kintor Pharmaceutical Limited (“the Company”) is a clinical-stage novel drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other androgen receptor-related, or AR-related diseases. The Company’s drug candidate, Proxalutamide, is a potential best-in-class drug undergoing phase III clinical trials in China and phase II clinical trials in the United States for metastatic castration-resistant prostate cancer, or mCRPC as well as clinical trials for breast cancer. Its mission is to become a global leader in the research, development and commercialisation of innovative therapies, focusing on indications with substantial unmet medical needs, in particular in the AR-related field. The Company had developed a pipeline of five clinical-stage drug candidates as of the Latest Practicable Date, for which are currently undergoing various phase I-III clinical trials in Greater China and other regions.